TY  - GEN
AU  - Druker,B J
AU  - Talpaz,M
AU  - Resta,D J
AU  - Peng,B
AU  - Buchdunger,E
AU  - Ford,J M
AU  - Lydon,N B
AU  - Kantarjian,H
AU  - Capdeville,R
AU  - Ohno-Jones,S
AU  - Sawyers,C L
TI  - Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
SN  - 0028-4793
PY  - 2001///0412
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Benzamides
KW  - Blood Cell Count
KW  - Dose-Response Relationship, Drug
KW  - Enzyme Inhibitors
KW  - Female
KW  - Fusion Proteins, bcr-abl
KW  - antagonists & inhibitors
KW  - Humans
KW  - Imatinib Mesylate
KW  - Interferon-alpha
KW  - therapeutic use
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - blood
KW  - Male
KW  - Middle Aged
KW  - Phosphorylation
KW  - Piperazines
KW  - Protein-Tyrosine Kinases
KW  - Pyrimidines
KW  - Recurrence
KW  - Remission Induction
KW  - methods
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S
UR  - https://doi.org/10.1056/NEJM200104053441401
ER  -